Table 1.

Characteristics of the included studies.

No.	Author	Year	Index	PA	EH	Optimal cutoff value	Se	Sp	AUC	TP	FP	FN	TN
1	Baron S	2016	ARR	107	79	45.6 pmol/mUI	1.000	0.939	NA	107	5	0	74
			PAC	107	79	360 pmol/L	0.857	0.951	NA	92	4	15	75
2	Baron S	2018	PAC	82	77	308 pmol/L	0.904	0.915	0.970	74	7	8	70
			ARR	82	77	64.5pmol/mU	0.873	1.000	0.988	72	0	10	77
3	Cheng Z Y	2021	ARR	57	70	6.5 pg/mL	0.942	0.78	0.902	54	15	3	55
			PAC	57	70	24 pg/mL	0.872	0.788	0.876	50	15	7	55
4	Fan Jing	2020	UAC	55	78	11.6 μg/24h	0.509	0.808	0.659	28	15	27	63
			UARR	55	78	4.63(μg/24h)/(μg/L/h)	0.855	0.821	0.906	47	14	8	64
5	Fries C M	2020	PAC	32	67	83 pmol/L	0.969	0.925	NA	31	5	1	62
			ARR	32	67	53 pmol/mU	0.969	0.597	NA	31	27	1	40
6	Fuss C T	2021	PAC	103	84	68ng/L	0.796	0.893	0.908	82	9	21	75
7	Guo Z	2018	ARR	29	8	55 pmol/mU	0.931	0.875	NA	27	1	2	7
8	Juutilainen Auni	2014	ARR	8	31	44 pmol/ng	1.000	0.84	0.970	8	5	0	26
9	Ma W	2019	UARR	60	353	1.11(μg/24h)/(μIU/ml)	0.917	0.890	0.947	55	39	5	314
			ARR	60	353	2.60(ng/dl)/(μIU/ml)	0.933	0.901	0.958	56	35	4	318
			UAC	60	353	7.13 μg/24 h	0.783	0.567	0.725	47	153	13	200
10	Travers S	2019	UAC	64	107	65 nmol/24 h	0.766	0.785	0.864	49	23	15	84
11	Xu Wen	2019	ARR	27	333	NA	0.910	0.963	NA	25	12	2	321
12	Zhao Lin	2019	ARR	143	232	13.84 (ng/dl)/(ng/ml·h)	0.790	0.783	0.837	113	50	30	182
			PAC	143	232	4.29 ng/dl	0.696	0.906	0.807	100	22	43	210

PA, Primary aldosteronism; EH, essential hypertension; Se, sensitivity; Sp, specificity; AUC, area under the receiver operating characteristic curve; TP, true positive; FP, false positive; TN, true negative; FN, false negative.